Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.vaccine.2021.03.022 http://scihub22266oqcxt.onion/10.1016/j.vaccine.2021.03.022 33781600!7938738!33781600     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vaccine 2021 ; 39 (17): 2458-2466 Nephropedia Template TP {{tp|p=33781600|t=2021. NIH funding for vaccine readiness before the COVID-19 pandemic |pdf=|usr=}}{{33781600}} gab.com Text NIH funding for vaccine readiness before the COVID-19 pandemic JO: Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=33781600 #FOAvip Rapid development of vaccines for COVID-19 has relied on the application of existing vaccine technologies. This work examines the maturity of ten technologies employed in candidate vaccines (as of July 2020) and NIH funding for published research on these technologies from 2000-2019. These technologies vary from established platforms, which have been used successfully in approved products, to emerging technologies with no prior clinical validation. A robust body of published research on vaccine technologies was supported by 16,358 fiscal years of NIH funding totaling $17.2 billion from 2000-2019. During this period, NIH funding for published vaccine research against specific pandemic threats such as coronavirus, Zika, Ebola, and dengue was not sustained. NIH funding contributed substantially to the advance of technologies available for rapid development of COVID-19 vaccines, suggesting the importance of sustained public sector funding for foundational technologies in the rapid response to emerging public health threats. Twit Text FOAVip NIH funding for vaccine readiness before the COVID-19 pandemic ????Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=33781600 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33781600 #FOAvip English Wikipedia <ref>{{Cite pmid|33781600}}</ref> NIH funding for vaccine readiness before the COVID-19 pandemic #MMPMID33781600 Kiszewski AE; Cleary EG; Jackson MJ; Ledley FD Vaccine 2021[Apr]; 39 (17): 2458-2466 PMID33781600show ga Rapid development of vaccines for COVID-19 has relied on the application of existing vaccine technologies. This work examines the maturity of ten technologies employed in candidate vaccines (as of July 2020) and NIH funding for published research on these technologies from 2000-2019. These technologies vary from established platforms, which have been used successfully in approved products, to emerging technologies with no prior clinical validation. A robust body of published research on vaccine technologies was supported by 16,358 fiscal years of NIH funding totaling $17.2 billion from 2000-2019. During this period, NIH funding for published vaccine research against specific pandemic threats such as coronavirus, Zika, Ebola, and dengue was not sustained. NIH funding contributed substantially to the advance of technologies available for rapid development of COVID-19 vaccines, suggesting the importance of sustained public sector funding for foundational technologies in the rapid response to emerging public health threats. |*COVID-19[MESH] |*Vaccines[MESH] |*Zika Virus[MESH] |*Zika Virus Infection/epidemiology/prevention & control[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH] |Pandemics[MESH]NIH funding for vaccine readiness before the COVID-19 pandemic (epmc).pdf DeepDyve Pubget Overpricing